Head-to-head · Value Score
CoreAge Rx vs NuuVim
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, NuuVim a 75. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameNuuVim
#140 · Grade C+ · Fair Price
Est. first month
From $79/mo (all doses, 3-month plan, new patients only, compounded)
Save ~94% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 75 — an est. $99/mo first month, with no teaser step-up baked in. NuuVim isn't out of it: Shoppers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | NuuVim |
|---|---|---|
| Value Score | 93 (A+) | 75 (C+) |
| Est. first month | $99/mo | From $79/mo (all doses, 3-month plan, new patients only, compounded) |
| Save vs brand-name | ~89% | ~94% |
| Semaglutide | $99/mo | From $79/mo (all doses, 3-month plan, new patients only, compounded) |
| Tirzepatide | $149/mo | From $133/mo (all doses, 3-month plan, new patients only, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
NuuVim
NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
Why it's a deal
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
The fine print
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own machine-readable index advertises pricing, FAQ and terms documents, and none of the three exists
- No state count is published
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to NuuVim.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.